Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) has received a consensus recommendation of “Hold” from the twelve ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $7.14.
Several brokerages have commented on TTPH. SunTrust Banks reiterated a “buy” rating and set a $10.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Wednesday, February 14th. Stifel Nicolaus dropped their target price on shares of Tetraphase Pharmaceuticals from $13.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. HC Wainwright dropped their target price on shares of Tetraphase Pharmaceuticals from $17.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 14th. B. Riley began coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, February 12th. They set a “buy” rating and a $11.00 target price for the company. Finally, Gabelli upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 29th.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 7,167 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $6.21, for a total transaction of $44,507.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.
NASDAQ:TTPH traded down $0.07 during trading hours on Tuesday, hitting $3.08. 376,450 shares of the stock were exchanged, compared to its average volume of 1,294,694. Tetraphase Pharmaceuticals has a twelve month low of $2.05 and a twelve month high of $8.76. The company has a market cap of $158.91, a price-to-earnings ratio of -1.17 and a beta of 2.61.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last posted its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.18. Tetraphase Pharmaceuticals had a negative return on equity of 90.75% and a negative net margin of 1,187.17%. The firm had revenue of $2.53 million for the quarter, compared to the consensus estimate of $2.26 million. analysts forecast that Tetraphase Pharmaceuticals will post -1.58 EPS for the current fiscal year.
Tetraphase Pharmaceuticals Company Profile
Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.